OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer
Status:
Recruiting
Trial end date:
2027-09-30
Target enrollment:
Participant gender:
Summary
This clinical trial aims to evaluate the efficacy, safety, and exploratory measures of
liposomal doxorubicin and carboplatin combination therapy in the adjuvant setting for early
stage triple negative breast cancer (TNBC) patients.
The primary objective is to determine the effectiveness of liposomal doxorubicin and
carboplatin in reducing the risk of recurrence for early stage TNBC patients.
The secondary objectives involve characterizing the safety and toxicity profile of the
combination therapy. Adverse events rates will be assessed using the Common Terminology
Criteria for Adverse Events (CTCAE) version 5.0.
The exploratory objectives of the study focus on evaluating changes in circulating tumor DNA
(ctDNA). This measure will provide insights into the potential utility of ctDNA as a
biomarker for treatment response and disease progression.
By addressing these objectives, the study aims to contribute to the understanding of the
benefits and risks associated with liposomal doxorubicin and carboplatin combination therapy
in the adjuvant setting for early stage TNBC, potentially leading to improved treatment
outcomes and patient care.